A plain language summary of Part A of the LILAC study of litifilimab for treating systemic lupus erythematosus

This Plain Language Summary of Publication article (PLSP) from Immunotherapy, describes the main results from Part A of the LILAC study, a Phase 2 trial investigating litifilimab, an antibody treatment, for different forms of lupus. The study compared various doses of litifilimab with a placebo to evaluate its effectiveness and monitored potential side effects to assess safety. The findings from Part A were published in 2022.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus’ and was published in the New England Journal of Medicine.

Visit NEJM using the link to read the original article.

• LILAC
• Litifilimab
• plain language summary
• systemic lupus erythematosus